UPDATE 1-Vivus' 2nd erectile dysfunction drug trial meets goals

* Co says drug avanafil improved erectile function

* Drug effective in 15 min and beyond 6 hours after dosing

* Shares up 5 pct in pre-mkt trade

June 7 (Reuters) - Vivus Inc VVUS.O said a second late-stage study of its erectile dysfunction drug met the main goals of improving erectile function score across the two doses that were studied in the trial.

The trial, named REVIVE-Diabetes (TA-302), tested the safety and efficacy of the drug avanafil in 390 men with diabetes and erectile dysfunction.

The study showed statistically significant improvement in erectile function and successful intercourse in 15 minutes and beyond six hours after dosing, the company said in a statement.

Last November, data from the first late-stage study -- named REVIVE (TA-301) -- on the drug showed it met the main trial goals and was effective in 30 minutes or less. [ID:nN18109272]

Commonly reported side effects included headache, nasopharyngitis, flushing, sinus congestion, sinusitis and dyspepsia. There were no drug-related serious adverse events in the study.

The company is conducting two more trials on avanafil, one in men who have undergone radical prostatectomy and an open-label safety study.

In total, the late-stage avanafil clinical program will enroll about 1,300 patients, Vivus said.

Shares of the company were up 5 percent to $12.94 in pre-market trade. They closed at $12.35 Friday on Nasdaq. (Reporting by Esha Dey in Bangalore; Editing by Prem Udayabhanu)